1. Home
  2. SCLX vs CLGN Comparison

SCLX vs CLGN Comparison

Compare SCLX & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • CLGN
  • Stock Information
  • Founded
  • SCLX 2011
  • CLGN 2004
  • Country
  • SCLX United States
  • CLGN Israel
  • Employees
  • SCLX N/A
  • CLGN N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • CLGN Industrial Specialties
  • Sector
  • SCLX Health Care
  • CLGN Health Care
  • Exchange
  • SCLX Nasdaq
  • CLGN Nasdaq
  • Market Cap
  • SCLX 35.7M
  • CLGN 33.8M
  • IPO Year
  • SCLX N/A
  • CLGN N/A
  • Fundamental
  • Price
  • SCLX $18.73
  • CLGN $2.23
  • Analyst Decision
  • SCLX Strong Buy
  • CLGN Strong Buy
  • Analyst Count
  • SCLX 3
  • CLGN 2
  • Target Price
  • SCLX $367.50
  • CLGN $11.50
  • AVG Volume (30 Days)
  • SCLX 309.9K
  • CLGN 250.5K
  • Earning Date
  • SCLX 08-13-2025
  • CLGN 11-26-2025
  • Dividend Yield
  • SCLX N/A
  • CLGN N/A
  • EPS Growth
  • SCLX N/A
  • CLGN N/A
  • EPS
  • SCLX N/A
  • CLGN N/A
  • Revenue
  • SCLX $44,236,000.00
  • CLGN $2,402,000.00
  • Revenue This Year
  • SCLX $89.26
  • CLGN $1,617.28
  • Revenue Next Year
  • SCLX $203.95
  • CLGN $83.54
  • P/E Ratio
  • SCLX N/A
  • CLGN N/A
  • Revenue Growth
  • SCLX N/A
  • CLGN 248.62
  • 52 Week Low
  • SCLX $3.60
  • CLGN $1.31
  • 52 Week High
  • SCLX $39.90
  • CLGN $4.99
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 46.04
  • CLGN 40.00
  • Support Level
  • SCLX $14.80
  • CLGN $2.21
  • Resistance Level
  • SCLX $30.90
  • CLGN $3.18
  • Average True Range (ATR)
  • SCLX 3.47
  • CLGN 0.22
  • MACD
  • SCLX -1.47
  • CLGN -0.06
  • Stochastic Oscillator
  • SCLX 23.68
  • CLGN 6.00

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

Share on Social Networks: